Analyst Price Targets — DYN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 10:42 am | Andrew Fein | H.C. Wainwright | $50.00 | $25.70 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN) |
| July 31, 2026 2:44 pm | — | Morgan Stanley | $45.00 | $24.64 | TheFly | Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley |
| May 15, 2026 12:23 pm | — | Evercore ISI | $33.00 | $17.79 | TheFly | Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI |
| May 13, 2026 10:28 am | — | Bernstein | $24.00 | $18.37 | TheFly | Dyne Therapeutics price target raised to $24 from $23 at Bernstein |
| March 2, 2026 10:37 pm | Keay Nakae | Chardan Capital | $38.00 | $16.15 | StreetInsider | Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN) |
| March 2, 2026 4:12 pm | Michael E Ulz | Morgan Stanley | $47.00 | $15.68 | StreetInsider | Dyne Therapeutics (DYN) PT Lowered to $47 at Morgan Stanley |
| December 15, 2025 1:38 pm | Gavin Clark-Gartner | Evercore ISI | $36.00 | $19.51 | TheFly | Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI |
| December 11, 2025 12:22 pm | — | Stifel Nicolaus | $39.00 | $19.69 | TheFly | Dyne Therapeutics price target raised to $39 from $36 at Stifel |
| December 10, 2025 11:49 am | — | Oppenheimer | $40.00 | $18.44 | TheFly | Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer |
| December 9, 2025 12:40 pm | William Pickering | Tudor Pickering | $23.00 | $19.09 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group |
Latest News for DYN
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
ADAR1 Capital Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 42,821 shares of the company's stock, valued at approximately $951,000. Other institutional investors
Deutsche Bank AG purchased a new position in Dyne Therapeutics, Inc. (NASDAQ: DYN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 242,392 shares of the company's stock, valued at approximately $5,384,000. Deutsche Bank AG owned approximately
WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment…
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DYN.
U.S. House Trading
No House trades found for DYN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.